(Q33499470)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

J C Adkins

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

D H Peters

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

A Markham

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 June 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1005-1037

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9179529%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-199753060-00007

3 November 2019

exact match

0 references

cites work

Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.

1 reference

12 December 2020

Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.

1 reference

12 December 2020

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

1 reference

12 December 2020

Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study

1 reference

12 December 2020

Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.

1 reference

12 December 2020

Late listeriosis after fludarabine plus prednisone treatment.

1 reference

12 December 2020

Successful treatment of Sézary syndrome with lymphomatous transformation to large cell lymphoma with fludarabine phosphate

1 reference

12 December 2020

Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine

1 reference

12 December 2020

Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma--the Jerusalem experience

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

1 reference

12 December 2020

In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells

1 reference

12 December 2020

Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas

1 reference

12 December 2020

Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.

1 reference

12 December 2020

Lysis pneumonopathy associated with the use of fludarabine phosphate

1 reference

12 December 2020

A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside

1 reference

12 December 2020

Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies

1 reference

12 December 2020

Fatal bone marrow necrosis following fludarabine administration in a patient with indolent lymphoma

1 reference

12 December 2020

Chronic lymphocytic leukemia

1 reference

12 December 2020

Treatment with fludarabine of chronic refractory lymphoid leukemia

1 reference

12 December 2020

Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia

1 reference

12 December 2020

Chemotherapy-Induced Neurotoxicity

1 reference

12 December 2020

Fludarabine treatment and transfusion-associated graft-versus-host disease

1 reference

12 December 2020

A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

1 reference

12 December 2020

Severe immunodeficiency in patients treated with fludarabine monophosphate

1 reference

12 December 2020

Treatment of low grade non-Hodgkin's lymphomas with fludarabine

1 reference

12 December 2020

Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism

1 reference

12 December 2020

Fludarabine in low-grade lymphoma.

1 reference

12 December 2020

A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids

1 reference

12 December 2020

Why do drugs work in CLL?

1 reference

12 December 2020

Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma

1 reference

12 December 2020

Fludarabine causing tumour lysis syndrome in chronic lymphocytic leukaemia

1 reference

12 December 2020

Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies

1 reference

12 December 2020

Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia

1 reference

12 December 2020

Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate

1 reference

12 December 2020

Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia

1 reference

12 December 2020

Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia

1 reference

12 December 2020

Fludarabine in the treatment of essential mixed cryoglobulinaemia

1 reference

12 December 2020

Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia

1 reference

12 December 2020

Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine

1 reference

12 December 2020

The potentiation of radiation response on murine tumor by fludarabine phosphate

1 reference

12 December 2020

Biologic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-d-arabinofuranosyladenine

1 reference

12 December 2020

Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients

1 reference

12 December 2020

Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells

1 reference

12 December 2020

Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells

1 reference

12 December 2020

Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy

1 reference

12 December 2020

FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia

1 reference

12 December 2020

FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.

1 reference

12 December 2020

Chronic lymphocytic leukemia: present status

1 reference

12 December 2020

Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.

1 reference

12 December 2020

Absence of minimal residual disease detectable by FACS, Southern blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine

1 reference

12 December 2020

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

1 reference

12 December 2020

Fludarabine-induced cytogenetic remission in prolymphocytic leukemia

1 reference

12 December 2020

First report of fludarabine in gamma-heavy chain disease

1 reference

12 December 2020

9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma

1 reference

12 December 2020

Advances in the biology and treatment of B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

12 December 2020

Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia.

1 reference

12 December 2020

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

12 December 2020

Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis

1 reference

12 December 2020

Fludarabine treatment in resistant Waldenstrom's macroglobulinemia

1 reference

12 December 2020

Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells

1 reference

12 December 2020

Fludarabine and plasma cell leukemia

1 reference

12 December 2020

Treatment of advanced chronic lymphocytic leukemia by fludarabine

1 reference

12 December 2020

Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. BCSH Blood Transfusion Task Force

1 reference

12 December 2020

Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience

1 reference

12 December 2020

Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues

1 reference

12 December 2020

Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity

1 reference

12 December 2020

Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate

1 reference

12 December 2020

Remission of leukaemic meningitis after fludarabine

1 reference

12 December 2020

Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine

1 reference

12 December 2020

Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine

1 reference

12 December 2020

Current guidelines for the management of aggressive non-Hodgkin's lymphoma

1 reference

12 December 2020

Prolonged bone marrow aplasia of refractory prolymphocytoid variant of B-cell chronic lymphocytic leukemia related to fludarabine treatment

1 reference

12 December 2020

Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine

1 reference

12 December 2020

Fludarabine monophosphate for prolymphocytic leukaemia

1 reference

12 December 2020

Key issues in the treatment of chronic lymphocytic leukaemia (CLL)

1 reference

12 December 2020

Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate

1 reference

12 December 2020

Prognostic and therapeutic advances in CLL management: the experience of the French Cooperative Group. French Cooperative Group on Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Neurological illness following treatment with fludarabine

1 reference

12 December 2020

Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy

1 reference

12 December 2020

Transfusion-associated graft-versus-host disease (TA-GVHD) in fludarabine-treated patients: is it time to irradiate blood component?

1 reference

12 December 2020

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

1 reference

12 December 2020

Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia.

1 reference

12 December 2020

1 reference

12 December 2020

Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.

1 reference

12 December 2020

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study

1 reference

12 December 2020

Fludarabine therapy in hairy cell leukemia.

1 reference

12 December 2020

Listerial brain abscess in a patient with chronic lymphocytic leukemia treated with fludarabine

1 reference

12 December 2020

Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts

1 reference

12 December 2020

Tumor lysis syndrome induced by fludarabine monophosphate: a case report

1 reference

12 December 2020

Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation

1 reference

12 December 2020

A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia

1 reference

12 December 2020

Acute renal failure as a consequence of urine stop flow in a patient with chronic lymphocytic leukemia after treatment with fludarabine

1 reference

12 December 2020

Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.

1 reference

12 December 2020

Fludarabine in Lymphoproliferative Disorders: The Royal Marsden Hospital Experience

1 reference

12 December 2020

Fludarabine therapy in macroglobulinemic lymphoma

1 reference

12 December 2020

The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo

1 reference

12 December 2020

A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia

1 reference

12 December 2020

Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines

1 reference

12 December 2020

Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy

1 reference

12 December 2020

Activity of Fludarabine Monophosphate in Patients With Advanced Mycosis Fungoides: A Southwest Oncology Group Study

1 reference

12 December 2020

FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Fludarabine in the management of malignant lymphomas

1 reference

12 December 2020

Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response

1 reference

12 December 2020

Fludarabine therapy in Waldenström's macroglobulinemia

1 reference

12 December 2020

Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro

1 reference

12 December 2020

Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.

1 reference

12 December 2020

FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity

1 reference

12 December 2020

Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.

1 reference

12 December 2020

Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone

1 reference

12 December 2020

IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study

1 reference

12 December 2020

Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes

1 reference

12 December 2020

Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia

1 reference

12 December 2020

Fludarabine phosphate for the treatment of low grade lymphoid malignancy

1 reference

12 December 2020

Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia

1 reference

12 December 2020

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

12 December 2020

Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia

1 reference

12 December 2020

Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells

1 reference

12 December 2020

Fludarabine: a new agent with major activity against chronic lymphocytic leukemia

1 reference

12 December 2020

Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine

1 reference

12 December 2020

Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia

1 reference

12 December 2020

Clinical staging of chronic lymphocytic leukemia

1 reference

12 December 2020

Crescentic glomerulonephritis associated with p-ANCA positivity in fludarabine-treated chronic lymphocytic leukaemia

1 reference

12 December 2020

Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation

1 reference

12 December 2020

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

12 December 2020

Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome

1 reference

12 December 2020

Neurotoxicity of purine analogs: a review

1 reference

12 December 2020

Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Pharmacokinetic study of fludarabine phosphate (NSC 312887)

1 reference

12 December 2020

Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice

1 reference

12 December 2020

Late-onset fatal neurological toxicity of fludarabine

1 reference

12 December 2020

Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia

1 reference

12 December 2020

Apoptosis in murine tumors treated with chemotherapy agents

1 reference

12 December 2020

Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine

1 reference

12 December 2020

Central nervous system toxicity of fludarabine phosphate.

1 reference

12 December 2020

Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial.

1 reference

12 December 2020

Intensive radio-chemotherapy with peripheral blood stem cell transplantation in young patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Pulmonary toxicity associated with fludarabine monophosphate

1 reference

12 December 2020

1 reference

12 December 2020

Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias

1 reference

12 December 2020

Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology

1 reference

12 December 2020

Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity

1 reference

12 December 2020

FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report

1 reference

12 December 2020

Radiosensitizing nucleosides

1 reference

12 December 2020

Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis

1 reference

12 December 2020

Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event

1 reference

12 December 2020

Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.

1 reference

12 December 2020

In vitro sensitivity of B-CLL cells to fludarabine and interferons

1 reference

12 December 2020

FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects

1 reference

12 December 2020

Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.

1 reference

12 December 2020

High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF)

1 reference

12 December 2020

Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

1 reference

12 December 2020

Fludarabine phosphate in refractory hairy cell leukemia

1 reference

12 December 2020

Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells.

1 reference

12 December 2020

Renal failure in a patient with chronic lymphocytic leukaemia treated with fludarabine

1 reference

12 December 2020

Type II mixed cryoglobulinemia treated with fludarabine

1 reference

12 December 2020

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

1 reference

12 December 2020

Effectiveness of fludarabine in end-stage prolymphocytic leukemia

1 reference

12 December 2020

Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies

1 reference

12 December 2020

High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia

1 reference

12 December 2020

Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia

1 reference

12 December 2020

A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.

1 reference

12 December 2020

Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine

1 reference

12 December 2020

Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells

1 reference

12 December 2020

Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase

1 reference

12 December 2020

Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment

1 reference

12 December 2020

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

12 December 2020

Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia

1 reference

12 December 2020

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

12 December 2020

Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia.

1 reference

12 December 2020

Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report

1 reference

12 December 2020

Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate

1 reference

12 December 2020

Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.

1 reference

12 December 2020

Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule

1 reference

12 December 2020

Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy

1 reference

12 December 2020

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

1 reference

12 December 2020

Sustained Response of Refractory Prolymphocytic Leukemia to Fludarabine

1 reference

12 December 2020

Gentamicin and fludarabine ototoxicity

1 reference

12 December 2020

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

12 December 2020

Clinical experience with fludarabine in leukaemia.

1 reference

12 December 2020

1 reference

12 December 2020

Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA

1 reference

12 December 2020

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

12 December 2020

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

12 December 2020

Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group

1 reference

12 December 2020

Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine

1 reference

12 December 2020

Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule

1 reference

12 December 2020

Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia

1 reference

12 December 2020